Showing posts with label biotech. Show all posts
Showing posts with label biotech. Show all posts

Monday, June 27, 2011

Fueling its future | Biobutanol holds promise for the next phase of Old Town Fuel & Fiber


By Carol Coultas

June 27, 2011

Four years ago, Dan Bird and Dick Arnold stood in an office within a 125-year-old paper mill and looked out the window to an empty plant. The room, once the controller’s office of previous occupant Georgia Pacific, was laid bare: no phones, no computers, no remnants at all of the Atlanta-based paper giant that vacated the Old Town mill to seek higher profits and lower energy costs in warmer climes.
The previous day, Bird and Arnold had attended a press conference with then Gov. John Baldacci, who announced new owners and new investment for the mill that at one time provided 400 jobs in this part of eastern Maine. It was up to the pair — both veterans of a changing paper industry — to bring the mill back to life.
“OK, I guess we’ve got a lot of work to do,” Bird recalls Arnold saying.
Dan Bird, director of IT and human resources for Old Town Fuel & FiberAnd so they have. Today the plant, now Old Town Fuel & Fiber, produces 600 tons of kraft pulp a day to feed a growing global demand. More importantly, the pulp process provides feedstock for a new sustainable fuel derived from wood: biobutanol, a renewable energy substitute for gasoline. The mill, which creates its own power, employs 205, and next month will begin building a biorefinery to make biobutanol for commercial consumption on a site that once housed tissue-making machines. The transformation from a typical paper mill to a value-added, sustainable and diversified manufacturer reflects the business philosophy of the company’s new private equity owner, Lynn Tilton of Patriarch Partners, and holds potential to drive the local economy once again.
“It’s a new chapter for us,” says Bird, who oversees Old Town Fuel & Fiber’s human resources and IT departments. “It was pretty bleak there for a while.”

Market forces

The bleak times started in 2006 when the market for pulp began to change at the same time paper-making operations were moving off shore. At the time, GP was producing about 600 tons a day of pulp, 200 of which fed its own machines to make napkins, toilet paper and paper towels under brand names such as Vanity Fair and Brawny. The other 400 tons were baled and sold as dry pulp. But rising energy costs prompted the company to consider warmer locations where balmy river water didn’t need as much energy or time as the frigid Penobscot’s to reach temperatures hot enough to generate steam to turn turbines and power the plant.
“There was a huge cost differential,” says Bird, between the Maine mill and its southern competition.
GP shuttered the plant, intending to raze it until Baldacci stepped in with a group of investors, pledging to use the mill as a learning laboratory to make cellulosic ethanol, another wood-based biofuel that had been pioneered at the University of Maine. Operating as Red Shield Environmental, the mill restarted the pulping operation in the spring of 2007, then closed in November to reconfigure two digesters to work sequentially, rather than independently — a key component in the pulping process that creates the organic byproduct used in cellulosic ethanol and biobutanol.
Pulp is rinsed multiple times before bleaching and drying. A byproduct of the operations produces feedstock for biobutanol, a gasoline alternative.But what worked in the lab didn’t quite work in the real world, says Bird. Glitches in the technology created delays. The band of investors, who bought the mill for $1 and lined up millions in financing, needed the revenue from making pulp to sustain it while the kinks were worked out of the cellulosic ethanol process. Facing new competition from overseas and a glut of paper, the domestic pulp market began a slide that didn’t turn around until 2010.
In spring of 2008, Red Shield applied for a $30 million Department of Energy grant to work on cellulosic ethanol — a gasoline additive, not a substitute like butanol — and was approved. But it was too late. In May, the mill shut down for scheduled maintenance, which cost the investors several million dollars, while the pulp market continued to plummet. The following month, nearly everyone was laid off and Red Shield filed for Chapter 11 bankruptcy.
“They just didn’t have the financial wherewithal to ride it out,” says Bird, who worked with Red Shield as its human resources director.
Financial wherewithal isn’t something Lynn Tilton worries much about. Fierce in her business dealings and flashy in her appearance, Tilton is on a crusade to bring back American manufacturing. Her New York private equity firm, Patriarch Partners, controls companies with a combined 12,000 employees and sales of $8 billion, according to the Wall Street Journal. Forbes is so intrigued by her, it’s begun a series to discover if she’s the country’s richest, self-made billionaire.
Her modus operandi is to scoop up distressed properties and turn them around, with a portfolio so extensive, she “basically lives on her jet” visiting her companies, says Bird. And that was part of the hook that attracted Tilton to easten Maine. The R&D under way at the University of Maine had the potential to lead to affordable jet fuel, a prospect Tilton was willing to wager on when she bought the mill at auction for almost $19 million.
But it was the mill’s energy self-reliance that first attracted her to Old Town, she says. “I really believe in putting idled assets and idled people back to work with innovative manufacturing,” she says. “Obviously you can’t do the same thing as before, but I’m not a believer of throwing out old industries and the people who worked in them. I’m drawn to those industries.
”What I liked a lot about Old Town was the work to become a greener facility,” she says. “With the biomass boiler, it’s a net generator of power, not a net user.”
FOCUS_butanol
A lesser draw was the potential to make biofuels, but Tilton sees the mill’s investment in that arena as part of a strategy to diversify revenue and maintain consistent cash flow for long-term success. Although the cellulosic ethanol didn’t work for Red Shield, it led to a new process, also developed by the University of Maine’s Forest Bioproducts Research Institute, to make biobutanol. Butanol is an industrial solvent, but when certain enzymes are added to a pulp byproduct and fermented, it becomes biobutanol, a gasoline substitute extracted from renewable organics.
According to Professor Hans Blaschek, head of the Center for Advanced Biorefinery Research at the University of Illinois, biobutanol produces less carbon dioxide, contains more energy density — a measure of how much energy it produces by volume — and fewer greenhouse gas emissions than conventional gasoline, and can be blended with gas or used alone in combustion engines. It also can be transported via existing gas pipelines, an advantage over ethanol.
Blaschek says a company he helped found, Chicago-based TetraVitae Bioscience, is one of a handful gearing up to commercially produce biobutanol.
“There are five or six companies in a dead heat to produce this on a commercial scale,” he says. “The market is huge.”
Bird says Old Town expects to produce biobutanol for commercial use within two years. Although he, too, sees a huge market (some experts put the number at $5 billion), the mill is too small to produce vast quantities of the biofuel. Instead, the greater value will come from refining the extract process in a proprietary technology that will belong to Patriarch Partners.
“We could potentially realize more value in licensing our intellectual property than the biorefinery and the pulp developments,” he says.

Under construction

In a far off corner of the mill where tissue machines once hummed, gleaming new equipment has been erected to bring the production of biobutanol that much closer to reality. Construction on the next phase of that $60 million project starts this summer, says Bird. He credits Tilton with convincing DOE to let her keep its $30 million grant and apply it to biobutanol research rather than cellulosic ethanol, and lining up matching funds.
“People here love her,” says Bird as he pauses to look at an array of photos taken during Tilton’s visit to the mill last July. Clad in black with waist-length blond hair cascading from under a hard hat, she acquiesced to safety standards by replacing her high-heel boots with hot-pink high-tops, helpfully provided by her makeup assistant, who accompanies Tilton everywhere.
A graduate of Yale and Columbia universities, Tilton is decisive about her companies. Bird says as long as Old Town Fuel & Fiber is operating in the black, it has her support. “She says she only flips and strips her men, not her mills,” quips Bird.
And she’s open to additional diversification of revenue for the old mill, including future potential as a data center site, offering data protection and storage separate from the physical locations of computers.
“There’s several companies that would like to take advantage of our behind-the-gate power, especially our power for cooling,” says Bird, noting it’s possible the mill would consider leasing space for a data center and selling its excess power directly to that tenant, rather than the grid. “There are ways this could make sense for us,” he says. “It’s all in keeping with diversifying the operation and the revenue stream.”

Qteros and UMass Amherst Bolster Patent Portfolio for Ethanol-Producing Microbe With Issued and Allowed Patents in the United States and Japan


June 27, 2011

MARLBOROUGH, Mass.June 27, 2011 /PRNewswire/ -- Qteros, Inc., the developer of a unique and highly efficient Consolidated Bioprocessing (CBP) platform for the lowest-cost production of cellulosic ethanol, and the University of Massachusetts Amherst, today announced two significant intellectual property (IP) advances that extend the patent estate for their unique ethanol-producing microorganism, Clostridium phytofermentans, also known as the Q Microbe®.
The United States Patent and Trademark Office issued US Patent 7,943,363 B2 covering genetic constructs of Clostridium phytofermentans. This patent is significant as it provides intellectual property protection for genomic development and the use of gene combinations in Clostridium phytofermentans and other microorganisms to enhance an organism's innate ability to hydrolyze biomass and improve the efficiency and yield of ethanol produced by an organism.
In a second but related advance, the Japanese Patent and Trademark Office allowed a patent titled, "Systems and Methods for Producing Biofuels and Related Materials."  The patent describes the novel creation of products through the fermentation of biomass by Clostridium phytofermentans. Patent allowance in Japan represents significant progress towards the broad, global protection of Clostridium phytofermentans bioprocessing outside of the United States. A patent has already been issued for this technology in the U.S.
Both patents are based on the discovery of Clostridium phytofermentans by microbiologists at the University of Massachusetts Amherst. Qteros is the exclusive licensee of the patent.
John A. McCarthy, Jr., Qteros' President and Chief Executive Officer, stated, "Each of these key patent achievements expands and further bolsters Qteros' already strong IP portfolio and represents the latest successes in our proactive and aggressive intellectual property strategy. Combined with the broad protection enabled by Qteros' current patent estate, these patents reinforce the uniqueness and the potential of our biological platform and enable Qteros to achieve an important milestone as we and our partners rapidly progress towards commercialization of our platform to produce lowest cost cellulosic ethanol at commercial scale."
Qteros' CBP Platform: Enabling Lowest Cost Production of Cellulosic Ethanol
The uniqueness of Qteros' CBP platform is centered on the Company's proprietary microorganism, the Q Microbe® (Clostridium phytofermentans) - a naturally occurring "biorefinery" that produces virtually all enzymes required for biomass degradation into pentose and hexose sugars, while simultaneously co-fermenting all these sugars into ethanol as its natural metabolic end product. The organism's innate biological ability to produce ethanol from biomass enables Qteros to focus its development efforts on optimizing the organism's effectiveness for industrial-scale production. This highly streamlined engineering solution therefore results in significantly lower operating and capital costs of production for producers versus other competitive technology solutions. Moreover, the Q Microbe® is feedstock flexible, producing high yields of cellulosic ethanol from a broad range of non-food biomass materials, including, among others, sugarcane bagasse, corn stover and cobs, and a broad variety of energy crops.
About Qteros, Inc.
Qteros' mission is to accelerate the global commercialization of large-scale, lowest-cost cellulosic ethanol production. Qteros has teamed with a core group of world-class strategic partners that complement and leverage our advanced microbiology and process engineering expertise. Working closely with its strategic partners, Qteros expects to rapidly scale its highly efficient, lowest-cost Consolidated Bioprocessing (CBP) platform for converting non-food biomass into biofuels. Qteros is funded by leading investors in the alternative energy industry including, among others, Venrock Associates, Battery Ventures, BP AE Ventures, Soros Fund Management LLC, and Valero Energy Corporation. For more information, please visit www.qteros.com.
About The University of Massachusetts
The University of Massachusetts Amherst is one of the nation's pre-eminent public research universities. More than 24,000 students from all 50 states and over 70 countries attend the university. Home to New England's premier honors college, UMass Amherst has more than 85 undergraduate majors, 68 master's and 48 doctoral degree programs– many the top programs in the nation and world. The faculty, dedicated teachers and world-renowned, recently received a record breaking $170 million in sponsored research. The student body is the most academically competitive in its history, and participates in over 240 co-curricular organizations. A recent facilities renaissance includes new buildings in the sciences, the arts, and recreation.

Wednesday, March 23, 2011

Greenwood, Arborgen team up to grow tree farms

 
By Anna Austin | March 23, 2011



Biotechnology tree seedling producer Arborgen Inc. and tree farm development company GreenWood Resources Inc. have teamed up to collaborate on the growth of purpose-grown hardwood trees in the Southeastern U.S.

The companies have collaborated in the past, which helped paved the way for this new partnership that will benefit both parties, according to Hunter Brown, GreenWood chief operating officer. “Greenwood has a long history in poplar genetics—we think [poplar] will be a viable, purpose-grown tree for the bioenergy industry—but we don’t have a platform for delivering that plant material,” he said. “Arborgen does. They have a strong network of nurseries and orchards throughout the Southeast U.S., and also have a strong network of customers—they sell hundreds of millions of seedlings of pines each year to landowners throughout the region.”

Arborgen also has customer bases in New Zealand and Australia.

On the other hand, Greenwood has a large network of timber investment customers and relationships, and has developed funds for short-rotation tree farming. “The synergies and overlap are significant in both of our efforts to cost-effectively deliver plant material to bioenergy opportunities as they develop,” Hunter said. “They already have the nursery and orchard business; we already have the plant material and can be ready without spending a lot of extra capital.”

Though the partnership with Arborgen will be focused on the Southeastern U.S., Hunter said there is solid activity in the energy tree sector outside of the country, mainly because of stronger government signals. “If you look at the industry on a global level, it’s certainly developing with more stable, predictable policies and regulations, especially in Europe, South America and Chile in particular, where economic fundamentals make dedicated biomass crops economically feasible,” he said. “In the U.S., in general, the policy and regulations have been a little less certain, especially over the last year with budgetary cutbacks and policy reassessments.”

Hunter believes the fiber produced from dedicated tree farms in the U.S. will be delivered to conversion facilities outside of the U.S. in significant portions.

He added that GreenWood and Arborgen expect to begin developing dedicated tree farm plant material in 2012, as 2011 will be mostly a scale-up year in the nurseries. 

Tuesday, March 22, 2011

Verenium, Shorn of Biofuels Business, Returns to San Diego and its Diversa Roots

http://www.xconomy.com/san-diego/2011/03/22/verenium-shorn-of-biofuels-business-returns-to-san-diego-and-its-diversa-roots/?single_page=true


By Bruce V. Bigelow


March 22, 2011

It felt like something was coming to an end last July, when energy giant BP said it was paying $98.3 million to acquire the cellulosic biofuels business of Cambridge, MA-based Verenium (NASDAQ: VRNM). But as Verenium consolidates its headquarters and remaining operations in San Diego, incoming CEO James Levine told me in so many words that what happened was not the end, but perhaps the end of the beginning for the industrial biotech.
Selling the cellulosic biofuels business and giving up Verenium’s goal of building an ethanol plant “surprised a lot of people,” Levine conceded when we met. “I think it was such a focus of our story that we knew it was going to take some time to let people understand the gem that we remain.”
Levine, who became Verenium’s chief executive after serving two years as its CFO, says the company is now “at a sort of inflection point—where we are an independent company and we’re kind of getting the word out about what we are.”
Verenium was created amid great expectations in 2007 with the merger of the ethanol biofuel expertise of Cambridge, MA-based Celunol and an enormous collection of enzyme samples and expertise amassed at San Diego-based Diversa. A year later, Verenium forged a crucial partnership with BP to develop cellulosic ethanol production facilities throughout the U.S. BP later provided an additional $45 million toward construction of a cellulosic ethanol plant near Tampa, FL.
But Verenium’s plans faltered during the Great Recession as the company sought to raise the roughly $400 million needed to build the Florida ethanol plant. Federal energy loan guarantees needed to finance the project failed to materialize, and Levine says, “We had great technology, and we had a great partner. But without funding we had to sell the business and let BP build the plant.”
Today Verenium has about 90 employees at its San Diego facility, which will become the company’s official headquarters on June 1, after Levine moves his family here from Boston. As a reorganized public company, Verenium has outgrown the role of a technology-developing startup that incurs regular losses. But it isn’t exactly a robust operating company, either. Verenium posted a $13.5 million operating loss in 2010, and has almost $75 million in debt. It also has nearly $88 million in cash left from its deal with BP.
“We’re in this spot where there is really only one way to go,” Levine says. “We have to go forward to profitability.”
For the coming year, Levine has set a number of goals: broaden and diversify the company’s line of industrial enzyme products, sign two new corporate partnerships, improve Verenium’s manufacturing through limited investments, control expenses, get at least two new products submitted for regulatory approval, and continue to address the company’s outstanding debt.
Levine’s prime directive is to refocus Verenium on “the incredible enzyme technology that Diversa created, and to make money from it.”
Diversa, which was founded in San Diego in 1994, has amassed billions of industrial enzymes, created by mining the genomes of organisms collected from deep sea thermal vents, Arctic tundra, soda lakes, and other far-flung corners of the world. Such enzymes are typically used as catalysts that act in highly specific ways to make certain biochemical reactions and processes possible.
Diversa had begun to develop a broad industrial enzyme business at the time of its 2007 merger with Cambridge, MA-based Celunol. But the enzymes Diversa had developed for breaking down cellulosic biomass were considered the crucial part of the deal, and they still are. Levine says BP got rights to the cellulosic enzymes—along with a copy of the entire Verenium enzyme library as part of its $98.3 million buyout of Verenium’s biofuels business.
So what’s the difference between Verenium in 2011 and Diversa in 2006?
“Diversa had a business model that aspired to be a products business,” Levine said. “But when you look at their revenue streams, it was largely from contract research.”
Today, Levine says Verenium is generating 90 to 95 percent of its revenue from nine products, industrial enzymes developed for target markets in animal health and nutrition, grain processing (into biofuels or beverage alcohols), and oil seed processing for edible oils. Such sales amounted to $50.3 million in 2010—double the $25 million that Verenium generated from product sales in 2007.
Levine, a former Goldman Sachs banker, is taking a pragmatic approach that recognizes Verenium’s technology and vast enzyme library has enormous potential value—but it can only be realized by building a commercial operating business that targets existing markets for industrial enzymes. Though last year’s deal with BP did not preclude Verenium from moving back into the cellulosic biofuels business, “I’d rather come up with the next big thing in animal health and nutrition, where it’s a $400 million or $500 million market,” Levine says. “I can double, triple, quadruple our revenue without having to touch markets [such as cellulosic ethanol] that don’t exist today a whole lot faster and with a whole lot more certainty.”
So it’s back to the future for Verenium, which has returned to its original focus on developing industrial enzymes. When we talk about our technology, we still say it’s very much about enzyme discovery in nature,” Levine said. “It’s very much about using the libraries that Diversa went out and created, and we continue to create libraries. But we no longer have the luxury of talking about ourselves as a platform technology developer, even though we are. We cannot move backwards. We have to move forward to being a profitable and sustainable enzyme seller.”